Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement.

Nascimbeni F, Dionisi Vici C, Vespasiani Gentilucci U, Angelico F, Nobili V, Petta S, Valenti L; AISF Rare Diseases Committee.

Dig Liver Dis. 2020 Jan 2. pii: S1590-8658(19)30952-1. doi: 10.1016/j.dld.2019.12.005. [Epub ahead of print] Review.

PMID:
31902560
2.

Outcomes of liver transplant for adults with Wilson's disease.

Ferrarese A, Morelli MC, Carrai P, Milana M, Angelico M, Perricone G, Belli LS, Marrone G, Grieco A, Martini S, Manini MA, Fagiuoli S, Toniutto P, Galeota Lanza A, Bhoori S, Petta S, Giannini EG, Burra P.

Liver Transpl. 2020 Jan 4. doi: 10.1002/lt.25714. [Epub ahead of print]

PMID:
31901209
3.

Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons with HIV infection and Compensated Advanced Chronic Liver Disease.

Merchante N, Saroli Palumbo C, Mazzola G, Pineda JA, Téllez F, Rivero-Juárez A, Ríos-Villegas MJ, Maurice JB, Westbrook RH, Judge R, Guaraldi G, Schepis F, Perazzo H, Rockstroh J, Boesecke C, Klein MB, Cervo A, Ghali P, Wong P, Petta S, De Ledinghen V, Macías J, Sebastiani G.

Clin Infect Dis. 2019 Dec 9. pii: ciz1181. doi: 10.1093/cid/ciz1181. [Epub ahead of print]

PMID:
31813962
4.

The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives.

Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S.

Int J Mol Sci. 2019 Nov 9;20(22). pii: E5613. doi: 10.3390/ijms20225613. Review.

5.

Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives.

Pennisi G, Celsa C, Spatola F, Dallio M, Federico A, Petta S.

Int J Environ Res Public Health. 2019 Nov 7;16(22). pii: E4334. doi: 10.3390/ijerph16224334. Review.

6.

Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients.

Sebastiani G, Cocciolillo S, Mazzola G, Malagoli A, Falutz J, Cervo A, Petta S, Pembroke T, Ghali P, Besutti G, Franconi I, Milic J, Cascio A, Guaraldi G.

HIV Med. 2019 Oct 23. doi: 10.1111/hiv.12799. [Epub ahead of print]

PMID:
31642599
7.

qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.

Liu F, Goh GB, Tiniakos D, Wee A, Leow WQ, Zhao JM, Rao HY, Wang XX, Wang Q, Wan WK, Lim KH, Romero-Gomez M, Petta S, Bugianesi E, Tan CK, Harrison SA, Anstee QM, Jason Chang PE, Wei L.

Hepatology. 2019 Oct 10. doi: 10.1002/hep.30986. [Epub ahead of print]

PMID:
31600834
8.

Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy.

Petta S, Rini F, Calvaruso V, Cammà C, Ciminnisi S, Di Marco V, Giannini EG, Grimaudo S, Maria Pipitone R, Craxì A.

Liver Int. 2019 Sep 11. doi: 10.1111/liv.14250. [Epub ahead of print]

PMID:
31507057
9.

Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study).

Calvaruso V, Bronte F, Ferraro D, Reina G, Conte E, Rini F, Magro B, Petta S, Di Marco V, Craxì A.

Liver Int. 2019 Dec;39(12):2240-2243. doi: 10.1111/liv.14242. Epub 2019 Sep 20.

PMID:
31502755
10.

Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.

Chen F, Esmaili S, Rogers G, Bugianesi E, Petta S, Marchesini G, Bayoumi A, Metwally M, Azardaryany MK, Coulter S, Choo JM, Younes R, Rosso C, Liddle C, Adams LA, Craxì A, George J, Eslam M.

Hepatology. 2019 Aug 23. doi: 10.1002/hep.30908. [Epub ahead of print]

PMID:
31442319
11.

Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease.

Grimaudo S, Pipitone RM, Pennisi G, Celsa C, Cammà C, Di Marco V, Barcellona MR, Boemi R, Enea M, Giannetti A, Spatola F, Marchesini G, Craxì A, Petta S.

Clin Gastroenterol Hepatol. 2019 Aug 13. pii: S1542-3565(19)30886-9. doi: 10.1016/j.cgh.2019.08.011. [Epub ahead of print]

PMID:
31419571
12.

Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.

Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Zheng MH, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry.

Clin Gastroenterol Hepatol. 2020 Jan;18(1):216-225.e5. doi: 10.1016/j.cgh.2019.05.051. Epub 2019 Jun 11.

PMID:
31195161
13.

Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease.

Pastore M, Grimaudo S, Pipitone RM, Lori G, Raggi C, Petta S, Marra F.

Front Pharmacol. 2019 May 29;10:604. doi: 10.3389/fphar.2019.00604. eCollection 2019. Review.

14.

Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.

Di Mauro S, Scamporrino A, Petta S, Urbano F, Filippello A, Ragusa M, Di Martino MT, Scionti F, Grimaudo S, Pipitone RM, Privitera G, Di Pino A, Scicali R, Valenti L, Dongiovanni P, Fracanzani A, Rabuazzo AM, Craxì A, Purrello M, Purrello F, Piro S.

Liver Int. 2019 Sep;39(9):1742-1754. doi: 10.1111/liv.14167. Epub 2019 Jun 26.

15.

Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.

Petta S, Wai-Sun Wong V, Bugianesi E, Fracanzani AL, Cammà C, Hiriart JB, Lai-Hung Wong G, Vergniol J, Wing-Hung Chan A, Giannetti A, Merrouche W, Lik-Yuen Chan H, Le-Bail B, Lombardi R, Guastella S, Craxì A, de Ledinghen V.

Am J Gastroenterol. 2019 Jun;114(6):916-928. doi: 10.14309/ajg.0000000000000153.

PMID:
31169533
16.

Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience.

Calvaruso V, Cacciola I, Licata A, Madonia S, Benigno R, Petta S, Bronte F, Conte E, Malizia G, Bertino G, Distefano M, Montineri A, Digiacomo A, Alaimo G, Cacopardo B, Davì A, Guarneri L, Scalisi I, Colletti P, Cartabellotta F, Portelli V, Prestileo T, Averna A, Iacobello C, Mondello L, Scifo G, Russello M, Squadrito G, Raimondo G, Cammà C, Craxì A, Di Marco V; RESIST-HCV (Rete Sicilia Selezione Terapia–HCV).

Am J Gastroenterol. 2019 Aug;114(8):1275-1282. doi: 10.14309/ajg.0000000000000266.

PMID:
31135449
17.

Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.

Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, Madonia S, Rossi M, Magro B, Rini F, Distefano M, Larocca L, Prestileo T, Malizia G, Bertino G, Benanti F, Licata A, Scalisi I, Mazzola G, Di Rosolini MA, Alaimo G, Averna A, Cartabellotta F, Alessi N, Guastella S, Russello M, Scifo G, Squadrito G, Raimondo G, Trevisani F, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group.

J Hepatol. 2019 Aug;71(2):265-273. doi: 10.1016/j.jhep.2019.03.027. Epub 2019 Apr 6.

PMID:
30959157
18.

PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients.

Dongiovanni P, Meroni M, Baselli G, Mancina RM, Ruscica M, Longo M, Rametta R, Cespiati A, Pelusi S, Ferri N, Ranzani V, Nobili V, Pihlajamaki J, Fracanzani AL, Badiali S, Petta S, Fargion S, Romeo S, Kozlitina J, Valenti L.

J Lipid Res. 2019 Jun;60(6):1144-1153. doi: 10.1194/jlr.P090449. Epub 2019 Mar 27.

PMID:
30918065
19.

Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease.

Buzzetti E, Petta S, Manuguerra R, Luong TV, Cabibi D, Corradini E, Craxì A, Pinzani M, Tsochatzis E, Pietrangelo A.

Liver Int. 2019 Jul;39(7):1325-1334. doi: 10.1111/liv.14096. Epub 2019 Mar 27.

PMID:
30851216
20.

Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.

Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, McCain MV, Meroni M, Fracanzani AL, Romagnoli R, Petta S, Grieco A, Miele L, Soardo G, Bugianesi E, Fargion S, Aghemo A, D'Ambrosio R, Xing C, Romeo S, De Francesco R, Reeves HL, Valenti LVC.

Sci Rep. 2019 Mar 6;9(1):3682. doi: 10.1038/s41598-019-39998-2.

21.

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.

Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, Dongiovanni P, Fracanzani AL, Badiali S, Maggioni M, Craxi A, Fargion S, Prati D, Nobili V, Bugianesi E, Romeo S, Pihlajamaki J, Petta S, Valenti L.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2310-2319.e6. doi: 10.1016/j.cgh.2019.01.027. Epub 2019 Jan 29.

PMID:
30708111
22.

FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage.

Lombardi R, Petta S, Pisano G, Dongiovanni P, Rinaldi L, Adinolfi LE, Acierno C, Valenti L, Boemi R, Spatola F, Craxì A, Fargion S, Fracanzani AL.

Clin Gastroenterol Hepatol. 2020 Feb;18(2):517-519. doi: 10.1016/j.cgh.2018.11.011. Epub 2018 Dec 8.

PMID:
30528844
23.

Expert opinion on managing chronic HCV in patients with cardiovascular disease.

Vassalle C, Petta S, Pepe A, Craxi A, Bondin M, Cacoub P.

Antivir Ther. 2018;23(Suppl 2):35-46. doi: 10.3851/IMP3248. Review.

24.

Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?

Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F, Petta S.

Pharmaceuticals (Basel). 2018 Nov 8;11(4). pii: E121. doi: 10.3390/ph11040121. Review.

25.

Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.

Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S.

Transplantation. 2019 Jan;103(1):22-27. doi: 10.1097/TP.0000000000002484. Review.

PMID:
30335697
26.

An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers.

Mazzotti A, Caletti MT, Brodosi L, Di Domizio S, Forchielli ML, Petta S, Bugianesi E, Bianchi G, Marchesini G.

J Hepatol. 2018 Nov;69(5):1155-1163. doi: 10.1016/j.jhep.2018.07.013. Epub 2018 Oct 2.

27.

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT), the Italian Society of Internal Medicine (SIMI).

Dig Liver Dis. 2018 Nov;50(11):1133-1152. doi: 10.1016/j.dld.2018.08.022. Epub 2018 Sep 12.

PMID:
30266305
28.

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI).

Intern Emerg Med. 2018 Dec;13(8):1139-1166. doi: 10.1007/s11739-018-1940-9. Epub 2018 Sep 25.

PMID:
30255464
29.

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI).

J Nephrol. 2018 Oct;31(5):685-712. doi: 10.1007/s40620-018-0523-1. Epub 2018 Sep 25.

PMID:
30255440
30.

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Minutolo R, Aghemo A, Chirianni A, Fabrizi F, Gesualdo L, Giannini EG, Maggi P, Montinaro V, Paoletti E, Persico M, Perticone F, Petta S, Puoti M, Raimondo G, Rendina M, Zignego AL; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI).

Infection. 2019 Feb;47(1):141-168. doi: 10.1007/s15010-018-1209-2. Epub 2018 Sep 25.

PMID:
30255389
31.

Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals.

Bazerbachi F, Haffar S, Wang Z, Cabezas J, Arias-Loste MT, Crespo J, Darwish-Murad S, Ikram MA, Olynyk JK, Gan E, Petta S, Berzuini A, Prati D, de Lédinghen V, Wong VW, Del Poggio P, Chávez-Tapia NC, Chen YP, Cheng PN, Yuen MF, Das K, Chowdhury A, Caballeria L, Fabrellas N, Ginès P, Kumar M, Sarin SK, Conti F, Andreone P, Sirli R, Cortez-Pinto H, Carvalhana S, Sugihara T, Kim SU, Parikh P, Chayama K, Corpechot C, Kim KM, Papatheodoridis G, Alsebaey A, Kamath PS, Murad MH, Watt KD.

Clin Gastroenterol Hepatol. 2019 Jan;17(1):54-64.e1. doi: 10.1016/j.cgh.2018.08.069. Epub 2018 Sep 7. Review.

PMID:
30196155
32.

Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease".

Petta S, Sebastiani G, de Ledinghen V.

J Hepatol. 2018 Nov;69(5):1203-1204. doi: 10.1016/j.jhep.2018.08.017. Epub 2018 Sep 5. No abstract available.

PMID:
30193923
33.

Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study.

Novo G, Macaione F, Giannitrapani L, Minissale MG, Bonomo V, Indovina F, Petta S, Soresi M, Montalto G, Novo S, Craxi A, Licata A.

Aliment Pharmacol Ther. 2018 Oct;48(7):740-749. doi: 10.1111/apt.14934. Epub 2018 Aug 10.

PMID:
30095177
34.

A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B.

El Sharkawy R, Thabet K, Lampertico P, Petta S, Mangia A, Berg T, Metwally M, Bayoumi A, Boonstra A, Brouwer WP, Smedile A, Abate ML, Loglio A, Douglas MW, Khan A, Santoro R, Fischer J, Leeming DJ, Liddle C, George J, Eslam M.

Aliment Pharmacol Ther. 2018 Sep;48(5):564-573. doi: 10.1111/apt.14866. Epub 2018 Jul 2.

35.

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H.

J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.

36.

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease.

Dongiovanni P, Meroni M, Mancina RM, Baselli G, Rametta R, Pelusi S, Männistö V, Fracanzani AL, Badiali S, Miele L, Grimaudo S, Petta S, Bugianesi E, Soardo G, Fargion S, Pihlajamäki J, Romeo S, Valenti L.

Hepatol Commun. 2018 Apr 25;2(6):666-675. doi: 10.1002/hep4.1192. eCollection 2018 Jun.

37.

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group.

Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28.

PMID:
29808463
38.

Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.

Petta S, Sebastiani G, Bugianesi E, Viganò M, Wong VW, Berzigotti A, Fracanzani AL, Anstee QM, Marra F, Barbara M, Calvaruso V, Cammà C, Di Marco V, Craxì A, de Ledinghen V.

J Hepatol. 2018 Oct;69(4):878-885. doi: 10.1016/j.jhep.2018.05.019. Epub 2018 May 24.

PMID:
29802949
39.

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.

Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxì A, Di Marco V; Rete Sicilia Selezione Terapia–HCV (RESIST-HCV).

Gastroenterology. 2018 Aug;155(2):411-421.e4. doi: 10.1053/j.gastro.2018.04.008. Epub 2018 Apr 12.

PMID:
29655836
40.

Liver and Statins: A Critical Appraisal of the Evidence.

Licata A, Giammanco A, Minissale MG, Pagano S, Petta S, Averna M.

Curr Med Chem. 2018;25(42):5835-5846. doi: 10.2174/0929867325666180327095441. Review.

PMID:
29589533
41.

Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.

Petta S, Di Marco V, Pipitone RM, Grimaudo S, Buscemi C, Craxì A, Buscemi S.

Liver Int. 2018 Nov;38(11):2060-2068. doi: 10.1111/liv.13743. Epub 2018 May 7.

PMID:
29577560
42.

Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.

Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A.

J Hepatol. 2018 Jul;69(1):18-24. doi: 10.1016/j.jhep.2018.02.015. Epub 2018 Mar 2.

PMID:
29505844
43.

Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study.

Tuttolomondo A, Petta S, Casuccio A, Maida C, Corte VD, Daidone M, Di Raimondo D, Pecoraro R, Fonte R, Cirrincione A, Zafonte R, Cabibi D, Cammà C, Di Marco V, Licata A, Magliozzo F, Marchesini G, Merlino G, Craxì A, Pinto A.

Cardiovasc Diabetol. 2018 Feb 16;17(1):28. doi: 10.1186/s12933-018-0670-7.

44.

[Hepatitis C virus infections: is it only e liver disease?]

Petta S.

Recenti Prog Med. 2018 Jan;109(1):28-32. doi: 10.1701/2848.28751. Italian.

PMID:
29451519
45.

Is global elimination of HCV realistic?

Calvaruso V, Petta S, Craxì A.

Liver Int. 2018 Feb;38 Suppl 1:40-46. doi: 10.1111/liv.13668. Review.

PMID:
29427499
46.

Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.

Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, Pelusi S, Pingitore P, Badiali S, Maggioni M, Mannisto V, Grimaudo S, Pipitone RM, Pihlajamaki J, Craxi A, Taube M, Carlsson LMS, Fargion S, Romeo S, Kozlitina J, Valenti L.

J Intern Med. 2018 Apr;283(4):356-370. doi: 10.1111/joim.12719. Epub 2017 Dec 27.

47.

Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS.

Petta S, Ciresi A, Bianco J, Geraci V, Boemi R, Galvano L, Magliozzo F, Merlino G, Craxì A, Giordano C.

PLoS One. 2017 Nov 21;12(11):e0186136. doi: 10.1371/journal.pone.0186136. eCollection 2017.

48.

Evidence-Based Medicine and the Problem of Healthy Volunteers.

Marchesini G, Marchignoli F, Petta S.

Ann Hepatol. 2017 November-December,;16(6):832-834. doi: 10.5604/01.3001.0010.5272.

49.

Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.

Younes R, Rosso C, Petta S, Cucco M, Marietti M, Caviglia GP, Ciancio A, Abate ML, Cammà C, Smedile A, Craxì A, Saracco GM, Bugianesi E.

Liver Int. 2018 Apr;38(4):715-723. doi: 10.1111/liv.13612. Epub 2017 Nov 3.

50.

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.

Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammario A, Raimondo G, Filomia R, Coppola C, Amoruso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonia S, Cannizzaro M, Zignego AL, Monti M, Russo FP, Zanetto A, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M, Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, Giannini EG.

PLoS One. 2017 Oct 4;12(10):e0185728. doi: 10.1371/journal.pone.0185728. eCollection 2017.

Supplemental Content

Support Center